154 related articles for article (PubMed ID: 27346567)
1. Is premedication a necessity before galsulfase replacement therapy?
Ercan N; Bostanci IB; Ozmen S; Ertugrul A
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):200-2. PubMed ID: 27346567
[No Abstract] [Full Text] [Related]
2. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.
Guvenir H; Dibek Misirlioglu E; Capanoglu M; Buyuktiryaki B; Unal O; Toyran M; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(4):1156-1157. PubMed ID: 28689831
[No Abstract] [Full Text] [Related]
3. A Desensitization Method to Maintain Enzyme Replacement Therapy in Mucopolysaccharidosis Type VI.
Kör D; Şeker Yilmaz B; Bulut FD; Önenli Mungan N; Ufuk Altıntaş D
J Investig Allergol Clin Immunol; 2016; 26(2):130-2. PubMed ID: 27164636
[No Abstract] [Full Text] [Related]
4. Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.
Bekis Bozkurt H; Karakurt T; Cavkaytar O; Arga M
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):261-262. PubMed ID: 33992778
[No Abstract] [Full Text] [Related]
5. Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera).
Di Bona D; Albanesi M; Giliberti LA; Nico A; Rossi MP; Caiaffa MF; Macchia L
J Allergy Clin Immunol Pract; 2017; 5(3):821-822. PubMed ID: 27888036
[No Abstract] [Full Text] [Related]
6. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.
Arroabarren E; Aznal E; Anda M; Sanchez-Valverde F
Pediatr Allergy Immunol; 2019 Jun; 30(4):491-494. PubMed ID: 30817035
[No Abstract] [Full Text] [Related]
7. Successful desensitization in a type VI mucopolysaccharidosis patient with probable IgE-mediated allergy to galsulfase [Naglazyme].
Bégin P; Chapdelaine H; Lemyre E; Paradis L; Des Roches A
Ann Allergy Asthma Immunol; 2013 Jan; 110(1):55-6. PubMed ID: 23244660
[No Abstract] [Full Text] [Related]
8. Linezolid desensitization in a pediatric patient.
Guvenir H; Dibek Misirlioglu E; Toyran M; Kocabas CN
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):198. PubMed ID: 27325511
[No Abstract] [Full Text] [Related]
9. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
10. Family study of a novel mutation of mucopolysaccharidosis type VI with a severe phenotype and good response to enzymatic replacement therapy: Case report.
Ley-Martos M; Guerrero JM; Lucas-Javato M; Remón-García C; García-Lozano JR; Colón C; Crujeiras P; Rodrigues D; Paúl-Sánchez P; Macher HC
Medicine (Baltimore); 2018 Oct; 97(42):e12872. PubMed ID: 30335002
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
Furujo M; Kubo T; Kosuga M; Okuyama T
Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of systemic reactions extends beyond completion of rush immunotherapy.
Cook KA; Kelso JM; White AA
J Allergy Clin Immunol Pract; 2017; 5(6):1773-1775. PubMed ID: 28506424
[No Abstract] [Full Text] [Related]
13. Assessment of Antihistamines and Corticosteroids as Premedication in Rapid Drug Desensitization to Paclitaxel: Outcomes in 155 Procedures.
Lopez-Gonzalez P; Madrigal-Burgaleta R; Carpio-Escalona LV; Bernal-Rubio L; Guerra E; Berges-Gimeno MP; Alvarez-Cuesta E
J Allergy Clin Immunol Pract; 2018; 6(4):1356-1362. PubMed ID: 29248386
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
[TBL] [Abstract][Full Text] [Related]
15. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]).
Kim KH; Decker C; Burton BK
Pediatrics; 2008 Mar; 121(3):e714-7. PubMed ID: 18250117
[TBL] [Abstract][Full Text] [Related]
16. Current concepts in allergy: drug reactions.
Evans R; Kim K; Mahr TA
Curr Probl Pediatr; 1991; 21(5):185-92. PubMed ID: 2065523
[No Abstract] [Full Text] [Related]
17. Successful rapid desensitization to intravenous bevacizumab using a 14-step protocol: Case report.
Williams SJ; Khokhar A; Gharib A
J Allergy Clin Immunol Pract; 2017; 5(6):1746-1747. PubMed ID: 28606785
[No Abstract] [Full Text] [Related]
18. Enzyme replacement therapy for mucopolysaccharidosis VI--experience in Taiwan.
Lin HY; Chen MR; Chuang CK; Chen CP; Lin DS; Chien YH; Ke YY; Tsai FJ; Pan HP; Lin SJ; Hwu WL; Niu DM; Lee NC; Lin SP
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S421-7. PubMed ID: 20924685
[TBL] [Abstract][Full Text] [Related]
19. Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy.
Sun A; Alshuaibi W; Petroni D; Skoda-Smith S; Goldberg MJ; Hale S
J Allergy Clin Immunol Pract; 2018; 6(5):1749-1751. PubMed ID: 29426755
[No Abstract] [Full Text] [Related]
20. [Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].
Politei J; Schenone A; Blanco M; Szlago M
Arch Argent Pediatr; 2014 Jun; 112(3):258-62. PubMed ID: 24862809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
